

Peter F Billingsley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7727877/publications.pdf>

Version: 2024-02-01

66
papers

5,018
citations

126907

33
h-index

102487

66
g-index

67
all docs

67
docs citations

67
times ranked

3308
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial. <i>Lancet Infectious Diseases</i> , 2022, 22, 377-389.	9.1	44
2	Cryopreservation of Anopheles stephensi embryos. <i>Scientific Reports</i> , 2022, 12, 43.	3.3	3
3	Controlled human malaria infection (CHMI) outcomes in Kenyan adults is associated with prior history of malaria exposure and anti-schizont antibody response. <i>BMC Infectious Diseases</i> , 2022, 22, 86.	2.9	9
4	Multi-Dose Priming Regimens of PfSPZ Vaccine: Safety and Efficacy against Controlled Human Malaria Infection in Equatoguinean Adults. <i>American Journal of Tropical Medicine and Hygiene</i> , 2022, 106, 1215-1226.	1.4	16
5	Diagnostic performance and comparison of ultrasensitive and conventional rapid diagnostic test, thick blood smear and quantitative PCR for detection of low-density Plasmodium falciparum infections during a controlled human malaria infection study in Equatorial Guinea. <i>Malaria Journal</i> , 2022, 21, 99.	2.3	9
6	A First for Human Vaccinology: GMP Compliant Radiation Attenuation of Plasmodium falciparum Sporozoites for Production of a Vaccine Against Malaria. <i>Frontiers in Immunology</i> , 2022, 13, 851028.	4.8	4
7	Phagocytosis of Plasmodium falciparum ring-stage parasites predicts protection against malaria. <i>Nature Communications</i> , 2022, 13, .	12.8	12
8	Multidose Priming and Delayed Boosting Improve Plasmodium falciparum Sporozoite Vaccine Efficacy Against Heterologous P. falciparum Controlled Human Malaria Infection. <i>Clinical Infectious Diseases</i> , 2021, 73, e2424-e2435.	5.8	23
9	Immunogenicity and Protective Efficacy of Radiation-Attenuated and Chemo-Attenuated PfSPZ Vaccines in Equatoguinean Adults. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 104, 283-293.	1.4	49
10	Transient knockdown of Anopheles stephensi LRIM1 using RNAi increases Plasmodium falciparum sporozoite salivary gland infections. <i>Malaria Journal</i> , 2021, 20, 284.	2.3	6
11	Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity. <i>Nature</i> , 2021, 595, 289-294.	27.8	68
12	Understanding the benefits and burdens associated with a malaria human infection study in Kenya: experiences of study volunteers and other stakeholders. <i>Trials</i> , 2021, 22, 494.	1.6	8
13	Safety and PCR monitoring in 161 semi-immune Kenyan adults following controlled human malaria infection. <i>JCI Insight</i> , 2021, 6, .	5.0	17
14	Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial. <i>Nature Medicine</i> , 2021, 27, 1636-1645.	30.7	47
15	Knockout of Anopheles stephensi immune gene LRIM1 by CRISPR-Cas9 reveals its unexpected role in reproduction and vector competence. <i>PLoS Pathogens</i> , 2021, 17, e1009770.	4.7	8
16	Safety, Tolerability, and Immunogenicity of Plasmodium falciparum Sporozoite Vaccine Administered by Direct Venous Inoculation to Infants and Young Children: Findings From an Age De-escalation, Dose-Escalation, Double-blind, Randomized Controlled Study in Western Kenya. <i>Clinical Infectious Diseases</i> , 2020, 71, 1063-1071.	5.8	25
17	Serologic Markers of Previous Malaria Exposure and Functional Antibodies Inhibiting Parasite Growth Are Associated With Parasite Kinetics Following a Plasmodium falciparum Controlled Human Infection. <i>Clinical Infectious Diseases</i> , 2020, 70, 2544-2552.	5.8	33
18	Increase of Dose Associated With Decrease in Protection Against Controlled Human Malaria Infection by PfSPZ Vaccine in Tanzanian Adults. <i>Clinical Infectious Diseases</i> , 2020, 71, 2849-2857.	5.8	46

#	ARTICLE	IF	CITATIONS
19	A double-blind, placebo-controlled phase 1/2a trial of the genetically attenuated malaria vaccine PfSPZ-GA1. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	50
20	The Equatoguinean Malaria Vaccine Initiative: From the Launching of a Clinical Research Platform to Malaria Elimination Planning in Central West Africa. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 947-954.	1.4	13
21	Is Saglin a mosquito salivary gland receptor for <i>Plasmodium falciparum</i> ?. <i>Malaria Journal</i> , 2019, 18, 2.	2.3	14
22	Safety and Differential Antibody and T-Cell Responses to the <i>Plasmodium falciparum</i> Sporozoite Malaria Vaccine, PfSPZ Vaccine, by Age in Tanzanian Adults, Adolescents, Children, and Infants. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019, 100, 1433-1444.	1.4	61
23	Safety, Immunogenicity, and Protective Efficacy against Controlled Human Malaria Infection of <i>Plasmodium falciparum</i> Sporozoite Vaccine in Tanzanian Adults. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 99, 338-349.	1.4	114
24	Impact of Sickle Cell Trait and Naturally Acquired Immunity on Uncomplicated Malaria after Controlled Human Malaria Infection in Adults in Gabon. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 98, 508-515.	1.4	60
25	Advancing Global Health through Development and Clinical Trials Partnerships: A Randomized, Placebo-Controlled, Double-Blind Assessment of Safety, Tolerability, and Immunogenicity of PfSPZ Vaccine for Malaria in Healthy Equatoguinean Men. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 98, 308-318.	1.4	55
26	Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 2711-2716.	7.1	201
27	Safety and efficacy of PfSPZ Vaccine against <i>Plasmodium falciparum</i> via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 498-509.	9.1	258
28	Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. <i>Nature</i> , 2017, 542, 445-449.	27.8	332
29	Protection against <i>Plasmodium falciparum</i> malaria by PfSPZ Vaccine. <i>JCI Insight</i> , 2017, 2, e89154.	5.0	195
30	Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. <i>Nature Medicine</i> , 2016, 22, 614-623.	30.7	313
31	Safety, Immunogenicity, and Protective Efficacy of Intradermal Immunization with Aseptic, Purified, Cryopreserved <i>Plasmodium falciparum</i> Sporozoites in Volunteers Under Chloroquine Prophylaxis: A Randomized Controlled Trial. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 94, 663-673.	1.4	58
32	Optimizing Intradermal Administration of Cryopreserved <i>Plasmodium falciparum</i> Sporozoites in Controlled Human Malaria Infection. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 93, 1274-1284.	1.4	23
33	Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved <i>Plasmodium falciparum</i> sporozoites in malaria-naïve volunteers: effect of injection volume and dose on infectivity rates. <i>Malaria Journal</i> , 2015, 14, 306.	2.3	78
34	Impact of Malaria Preexposure on Antiparasite Cellular and Humoral Immune Responses after Controlled Human Malaria Infection. <i>Infection and Immunity</i> , 2015, 83, 2185-2196.	2.2	40
35	Lessons learnt from the first controlled human malaria infection study conducted in Nairobi, Kenya. <i>Malaria Journal</i> , 2015, 14, 182.	2.3	64
36	Robust, reproducible, industrialized, standard membrane feeding assay for assessing the transmission blocking activity of vaccines and drugs against <i>Plasmodium falciparum</i> . <i>Malaria Journal</i> , 2015, 14, 150.	2.3	18

#	ARTICLE	IF	CITATIONS
37	Direct venous inoculation of <i>Plasmodium falciparum</i> sporozoites for controlled human malaria infection: a dose-finding trial in two centres. <i>Malaria Journal</i> , 2015, 14, 117.	2.3	114
38	Progress with <i>Plasmodium falciparum</i> sporozoite (PfSPZ)-based malaria vaccines. <i>Vaccine</i> , 2015, 33, 7452-7461.	3.8	152
39	Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to <i>Plasmodium falciparum</i> using sporozoites administered by intramuscular injection. <i>Frontiers in Microbiology</i> , 2014, 5, 686.	3.5	95
40	Controlled Human Malaria Infection of Tanzanians by Intradermal Injection of Aseptic, Purified, Cryopreserved <i>Plasmodium falciparum</i> Sporozoites. <i>American Journal of Tropical Medicine and Hygiene</i> , 2014, 91, 471-480.	1.4	116
41	Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine. <i>Science</i> , 2013, 341, 1359-1365.	12.6	686
42	Controlled Human Malaria Infections by Intradermal Injection of Cryopreserved <i>Plasmodium falciparum</i> Sporozoites. <i>American Journal of Tropical Medicine and Hygiene</i> , 2013, 88, 5-13.	1.4	140
43	Infection and treatment immunizations for successful parasite vaccines. <i>Trends in Parasitology</i> , 2013, 29, 135-141.	3.3	35
44	Optimising Controlled Human Malaria Infection Studies Using Cryopreserved <i>P. falciparum</i> Parasites Administered by Needle and Syringe. <i>PLoS ONE</i> , 2013, 8, e65960.	2.5	80
45	Successful Human Infection with <i>P. falciparum</i> Using Three Aseptic <i>Anopheles stephensi</i> Mosquitoes: A New Model for Controlled Human Malaria Infection. <i>PLoS ONE</i> , 2013, 8, e68969.	2.5	26
46	Only the good die young: a novel paradigm for mosquito control. <i>Trends in Parasitology</i> , 2010, 26, 53-55.	3.3	3
47	IgM-antibody responses of chickens to salivary antigens of <i>Triatoma infestans</i> as early biomarkers for low-level infestation of triatomines. <i>International Journal for Parasitology</i> , 2010, 40, 1295-1302.	3.1	22
48	<i>Plasmodium falciparum</i> Malaria Challenge by the Bite of Aseptic <i>Anopheles stephensi</i> Mosquitoes: Results of a Randomized Infectivity Trial. <i>PLoS ONE</i> , 2010, 5, e13490.	2.5	42
49	Development of a metabolically active, non-replicating sporozoite vaccine to prevent <i>Plasmodium falciparum</i> malaria. <i>Hum Vaccin</i> , 2010, 6, 97-106.	2.4	258
50	Immunogenic Salivary Proteins of <i>Triatoma infestans</i> : Development of a Recombinant Antigen for the Detection of Low-Level Infestation of Triatomines. <i>PLoS Neglected Tropical Diseases</i> , 2009, 3, e532.	3.0	35
51	Antibody responses of domestic animals to salivary antigens of <i>Triatoma infestans</i> as biomarkers for low-level infestation of triatomines. <i>International Journal for Parasitology</i> , 2009, 39, 1021-1029.	3.1	39
52	Mosquitocidal vaccines: a neglected addition to malaria and dengue control strategies. <i>Trends in Parasitology</i> , 2008, 24, 396-400.	3.3	30
53	Rodent malaria parasites <i>Plasmodium chabaudi</i> and <i>P. vinckei</i> do not increase their rates of gametocytogenesis in response to mosquito probing. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2005, 272, 2397-2402.	2.6	12
54	Induced Immunity Against the Mosquito <i>Anopheles stephensi</i> (Diptera: Culicidae): Effects of Cell Fraction Antigens on Survival, Fecundity, and <i>Plasmodium berghei</i> (Eucoccidiida: Plasmodiidae) Transmission. <i>Journal of Medical Entomology</i> , 2002, 39, 207-214.	1.8	21

#	ARTICLE	IF	CITATIONS
55	Malaria Control with Genetically Manipulated Insect Vectors. <i>Science</i> , 2002, 298, 119-121.	12.6	221
56	Differential display of mRNAs associated with blood feeding in the midgut of the bloodsucking bug, <i>Triatoma infestans</i> . <i>Parasitology Research</i> , 2002, 88, 1026-1033.	1.6	24
57	Partial characterization of oligosaccharides expressed on midgut microvillar glycoproteins of the mosquito, <i>Anopheles stephensi</i> Liston. <i>Insect Biochemistry and Molecular Biology</i> , 2001, 31, 937-948.	2.7	33
58	A comparative survey of the hydrolytic enzymes of ectoparasitic and free-living mites. <i>International Journal for Parasitology</i> , 2000, 30, 19-27.	3.1	61
59	Detection and characterization of a mannan-binding lectin from the mosquito, <i>Anopheles stephensi</i> (Liston). <i>FEBS Journal</i> , 1999, 263, 360-366.	0.2	18
60	Hydrolytic enzymes of <i>Psoroptes cuniculi</i> (Delafond). <i>Insect Biochemistry and Molecular Biology</i> , 1999, 29, 25-32.	2.7	17
61	Induced immunity against the mosquito <i>Anopheles stephensi</i> Liston (Diptera: Culicidae): effects on mosquito survival and fecundity. <i>International Journal for Parasitology</i> , 1998, 28, 1721-1731.	3.1	31
62	2. Molecular targets in the insect midgut. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1994, 88, 136-140.	1.8	17
63	Kinetics of Expression of Two Major <i>Plasmodium berghei</i> Antigens in the Mosquito Vector, <i>Anopheles stephensi</i> . <i>Journal of Eukaryotic Microbiology</i> , 1993, 40, 569-576.	1.7	34
64	The Role of the Mosquito Peritrophic Membrane in Bloodmeal Digestion and Infectivity of <i>Plasmodium</i> Species. <i>Journal of Parasitology</i> , 1992, 78, 430.	0.7	118
65	Blood Digestion in the Mosquito, <i>Anopheles stephensi</i> Liston (Diptera: Culicidae): Activity and Distribution of Trypsin, Aminopeptidase, and α -Glucosidase in the Midgut. <i>Journal of Medical Entomology</i> , 1991, 28, 865-871.	1.8	104
66	Blood digestion in the mosquito, <i>Anopheles stephensi</i> liston (diptera: Culicidae): Partial characterization and post-feeding activity of midgut aminopeptidases. <i>Archives of Insect Biochemistry and Physiology</i> , 1990, 15, 149-163.	1.5	57